Wu Huai-Neng, Zhu Shuang-Yue, Zhang Li-Na, Shen Bian-Hong, Xu Lian-Lian
Department of Psychiatry, Affiliated Mental Health Center and Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou 310013, Zhejiang Province, China.
World J Psychiatry. 2024 Oct 19;14(10):1573-1582. doi: 10.5498/wjp.v14.i10.1573.
Major depressive disorder (MDD) is a substantial global health concern, and its treatment is complicated by the variability in individual response to antidepressants.
To consolidate research and clarify the impact of genetic variation on MDD treatment outcomes.
Adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic search across PubMed, EMBASE, Web of Science, and the Cochrane Library was conducted without date restrictions, utilizing key terms related to MDD, serotonin 1A receptor polymorphism (5-HTR1A), C-1019G polymorphism, and antidepressant response. Studies meeting inclusion criteria were thoroughly screened, and quality assessed using the Newcastle-Ottawa Scale. Statistical analyses, including and values, were used to evaluate heterogeneity and fixed-effect or random-effect models were applied accordingly.
The initial search yielded 1216 articles, with 11 studies meeting criteria for inclusion. Analysis of various genetic models showed no significant association between the 5-HTR1A C-1019G polymorphism and antidepressant efficacy. The heterogeneity was low to moderate, and no publication bias was detected through funnel plot symmetry and Egger's and Begg's tests.
This meta-analysis does not support a significant association between the 5-HTR1A C-1019G polymorphism and the efficacy of antidepressant treatment in MDD. The findings call for further research with larger cohorts to substantiate these results and enhance the understanding of antidepressant pharmacogenetics.
重度抑郁症（MDD）是一个重大的全球健康问题，其治疗因个体对抗抑郁药反应的变异性而变得复杂。
整合研究并阐明基因变异对MDD治疗结果的影响。
遵循系统评价和Meta分析的首选报告项目指南，在PubMed、EMBASE、科学网和考克兰图书馆进行无日期限制的系统检索，使用与MDD、血清素1A受体多态性（5-HTR1A）、C-1019G多态性和抗抑郁药反应相关的关键词。对符合纳入标准的研究进行全面筛选，并使用纽卡斯尔-渥太华量表评估质量。采用包括 和 值在内的统计分析来评估异质性，并相应应用固定效应或随机效应模型。
初步检索得到1216篇文章，其中11项研究符合纳入标准。对各种遗传模型的分析表明，5-HTR1A C-1019G多态性与抗抑郁药疗效之间无显著关联。异质性为低到中度，通过漏斗图对称性以及Egger检验和Begg检验未检测到发表偏倚。
这项Meta分析不支持5-HTR1A C-1019G多态性与MDD抗抑郁治疗疗效之间存在显著关联。这些发现呼吁进行更大样本量队列的进一步研究，以证实这些结果并增进对抗抑郁药物遗传学的理解。
